dulaglutide vs tirzepatide π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to for major cardiovascular events (12.2% 13.1%; HR 0.92). What π« EASD 2025: Tirzepatide (SURPASS-CVOT)
Pay in 4 interest-free payments of $5.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 18 - Aug 23






:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)


:max_bytes(150000):strip_icc()/Health-GettyImages-2112991930-7aba42b37c8641d3a76cb03100b26dda.jpg)






.png)








